Company Performance Metrics
Corixa is a developer of immunotherapeutics with a commitment to treating and preventing autoimmune diseases, cancer and infectious diseases by understanding and directing the immune system.
Having founded in 1994, the company conducted various preclinical development programs, including the BEXXAR® therapy and the MELACINE® vaccine.
Corixa is focused on immunotherapeutic products and has a broad technology platform enabling both fully integrated vaccine design and the use of its separate, proprietary product components on a standalone basis.
The company partners with numerous developers and marketers of pharmaceuticals, targeting products that are powered by Corixa™ technology with the goal of making its potential products available to patients around the world.
Corixa was acquired by GlaxoSmithKline on 12 July 2005, and GSK had formerly made use of the Corixa's MPL adjuvant in some of their vaccines. The company ceased operations in March 2006.
